Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 901 to 907 of 907 entries
Sorted by: Best Match Show Resources per page
Three-dimensional color Doppler acquisition of a highly vascular giant placental chorioangioma.

American journal of obstetrics and gynecology

Arora S, Khera N, Kaul A.
PMID: 34453931
Am J Obstet Gynecol. 2021 Aug 25; doi: 10.1016/j.ajog.2021.08.021. Epub 2021 Aug 25.

No abstract available.

Cite
Arora S, Khera N, Kaul A. Three-dimensional color Doppler acquisition of a highly vascular giant placental chorioangioma. Am J Obstet Gynecol. 2021;doi: 10.1016/j.ajog.2021.08.021.
Arora, S., Khera, N., & Kaul, A. (2021). Three-dimensional color Doppler acquisition of a highly vascular giant placental chorioangioma. American journal of obstetrics and gynecology, . https://doi.org/10.1016/j.ajog.2021.08.021
Arora, Saloni, et al. "Three-dimensional color Doppler acquisition of a highly vascular giant placental chorioangioma." American journal of obstetrics and gynecology vol. (2021). doi: https://doi.org/10.1016/j.ajog.2021.08.021
Arora S, Khera N, Kaul A. Three-dimensional color Doppler acquisition of a highly vascular giant placental chorioangioma. Am J Obstet Gynecol. 2021 Aug 25; doi: 10.1016/j.ajog.2021.08.021. Epub 2021 Aug 25. PMID: 34453931.
Copy Download .nbib Format: NLM
Lifelong exposure to residential greenspace and the premenstrual syndrome: A population-based study of Northern European women.

Environment international

Triebner K, Markevych I, Bertelsen RJ, Sved Skottvoll B, Hustad S, Forsberg B, Franklin KA, Holm M, Lindberg E, Heinrich J, Gómez Real F, Dadvand P.
PMID: 34781209
Environ Int. 2022 Jan;158:106975. doi: 10.1016/j.envint.2021.106975. Epub 2021 Nov 12.

BACKGROUND: The premenstrual syndrome (PMS) causes clinically relevant psychological and physical symptoms in up to 20% of women of reproductive age. To date, no studies have investigated the relationship between PMS and residential surrounding greenspace, although a green living...

Cite
Triebner K, Markevych I, Bertelsen RJ, et al. Lifelong exposure to residential greenspace and the premenstrual syndrome: A population-based study of Northern European women. Environ Int. 2021;158:106975doi: 10.1016/j.envint.2021.106975.
Triebner, K., Markevych, I., Bertelsen, R. J., Sved Skottvoll, B., Hustad, S., Forsberg, B., Franklin, K. A., Holm, M., Lindberg, E., Heinrich, J., Gómez Real, F., & Dadvand, P. (2022). Lifelong exposure to residential greenspace and the premenstrual syndrome: A population-based study of Northern European women. Environment international, 158106975. https://doi.org/10.1016/j.envint.2021.106975
Triebner, Kai, et al. "Lifelong exposure to residential greenspace and the premenstrual syndrome: A population-based study of Northern European women." Environment international vol. 158 (2022): 106975. doi: https://doi.org/10.1016/j.envint.2021.106975
Triebner K, Markevych I, Bertelsen RJ, Sved Skottvoll B, Hustad S, Forsberg B, Franklin KA, Holm M, Lindberg E, Heinrich J, Gómez Real F, Dadvand P. Lifelong exposure to residential greenspace and the premenstrual syndrome: A population-based study of Northern European women. Environ Int. 2022 Jan;158:106975. doi: 10.1016/j.envint.2021.106975. Epub 2021 Nov 12. PMID: 34781209.
Copy Download .nbib Format: NLM
Delving into defence: identifying the .

Microbial genomics

Vick SHW, Fabian BK, Dawson CJ, Foster C, Asher A, Hassan KA, Midgley DJ, Paulsen IT, Tetu SG.
PMID: 34788213
Microb Genom. 2021 Nov;7(11). doi: 10.1099/mgen.0.000671.

Competitive behaviours of plant growth promoting rhizobacteria (PGPR) are integral to their ability to colonize and persist on plant roots and outcompete phytopathogenic fungi, oomycetes and bacteria. PGPR engage in a range of antagonistic behaviours that have been studied...

Cite
Vick SHW, Fabian BK, Dawson CJ, et al. Delving into defence: identifying the . Microb Genom. 2021;7(11)doi: 10.1099/mgen.0.000671.
Vick, S. H. W., Fabian, B. K., Dawson, C. J., Foster, C., Asher, A., Hassan, K. A., Midgley, D. J., Paulsen, I. T., & Tetu, S. G. (2021). Delving into defence: identifying the . Microbial genomics, 7(11), . https://doi.org/10.1099/mgen.0.000671
Vick, Silas H W, et al. "Delving into defence: identifying the ." Microbial genomics vol. 7,11 (2021). doi: https://doi.org/10.1099/mgen.0.000671
Vick SHW, Fabian BK, Dawson CJ, Foster C, Asher A, Hassan KA, Midgley DJ, Paulsen IT, Tetu SG. Delving into defence: identifying the . Microb Genom. 2021 Nov;7(11). doi: 10.1099/mgen.0.000671. PMID: 34788213; PMCID: PMC8743541.
Copy Download .nbib Format: NLM
P047 The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient Reported Outcome Measure for Clinical Trials.

The American journal of gastroenterology

Seabury J, Weinstein J, Rosero S, Varma A, Wagner E, Zizzi C, Dilek N, McDermott M, Kaat A, Saubermann L, Temple L, Rogoff S, Heatwole C.
PMID: 35006174
Am J Gastroenterol. 2021 Dec 01;116:S12. doi: 10.14309/01.ajg.0000798788.08354.11.

BACKGROUND: In preparation for upcoming clinical trials involving patients with Crohn's disease (CD), we examine the validity, reliability and usability of the Crohn's Disease-Health Index (CD-HI). The CD-HI is a multifaceted, disease-specific patient reported outcome measure (PROM) designed to...

Cite
Seabury J, Weinstein J, Rosero S, et al. P047 The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient Reported Outcome Measure for Clinical Trials. Am J Gastroenterol. 2021;116:S12doi: 10.14309/01.ajg.0000798788.08354.11.
Seabury, J., Weinstein, J., Rosero, S., Varma, A., Wagner, E., Zizzi, C., Dilek, N., McDermott, M., Kaat, A., Saubermann, L., Temple, L., Rogoff, S., & Heatwole, C. (2021). P047 The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient Reported Outcome Measure for Clinical Trials. The American journal of gastroenterology, 116S12. https://doi.org/10.14309/01.ajg.0000798788.08354.11
Seabury, Jamison, et al. "P047 The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient Reported Outcome Measure for Clinical Trials." The American journal of gastroenterology vol. 116 (2021): S12. doi: https://doi.org/10.14309/01.ajg.0000798788.08354.11
Seabury J, Weinstein J, Rosero S, Varma A, Wagner E, Zizzi C, Dilek N, McDermott M, Kaat A, Saubermann L, Temple L, Rogoff S, Heatwole C. P047 The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient Reported Outcome Measure for Clinical Trials. Am J Gastroenterol. 2021 Dec 01;116:S12. doi: 10.14309/01.ajg.0000798788.08354.11. PMID: 35006174.
Copy Download .nbib Format: NLM
Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages.

PLoS pathogens

Tran TT, Mathmann CD, Gatica-Andrades M, Rollo RF, Oelker M, Ljungberg JK, Nguyen TTK, Zamoshnikova A, Kummari LK, Wyer OJK, Irvine KM, Melo-Bolívar J, Gross A, Brown D, Mak JYW, Fairlie DP, Hansford KA, Cooper MA, Giri R, Schreiber V, Joseph SR, Simpson F, Barnett TC, Johansson J, Dankers W, Harris J, Wells TJ, Kapetanovic R, Sweet MJ, Latomanski EA, Newton HJ, Guérillot RJR, Hachani A, Stinear TP, Ong SY, Chandran Y, Hartland EL, Kobe B, Stow JL, Sauer-Eriksson AE, Begun J, Kling JC, Blumenthal A.
PMID: 35007292
PLoS Pathog. 2022 Jan 10;18(1):e1010166. doi: 10.1371/journal.ppat.1010166. eCollection 2022 Jan.

A hallmark of Listeria (L.) monocytogenes pathogenesis is bacterial escape from maturing entry vacuoles, which is required for rapid bacterial replication in the host cell cytoplasm and cell-to-cell spread. The bacterial transcriptional activator PrfA controls expression of key virulence...

Cite
Tran TT, Mathmann CD, Gatica-Andrades M, et al. Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS Pathog. 2022;18(1):e1010166doi: 10.1371/journal.ppat.1010166.
Tran, T. T., Mathmann, C. D., Gatica-Andrades, M., Rollo, R. F., Oelker, M., Ljungberg, J. K., Nguyen, T. T. K., Zamoshnikova, A., Kummari, L. K., Wyer, O. J. K., Irvine, K. M., Melo-Bolívar, J., Gross, A., Brown, D., Mak, J. Y. W., Fairlie, D. P., Hansford, K. A., Cooper, M. A., Giri, R., Schreiber, V., Joseph, S. R., Simpson, F., Barnett, T. C., Johansson, J., Dankers, W., Harris, J., Wells, T. J., Kapetanovic, R., Sweet, M. J., Latomanski, E. A., Newton, H. J., Guérillot, R. J. R., Hachani, A., Stinear, T. P., Ong, S. Y., Chandran, Y., Hartland, E. L., Kobe, B., Stow, J. L., Sauer-Eriksson, A. E., Begun, J., Kling, J. C., & Blumenthal, A. (2022). Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS pathogens, 18(1), e1010166. https://doi.org/10.1371/journal.ppat.1010166
Tran, Thao Thanh, et al. "Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages." PLoS pathogens vol. 18,1 (2022): e1010166. doi: https://doi.org/10.1371/journal.ppat.1010166
Tran TT, Mathmann CD, Gatica-Andrades M, Rollo RF, Oelker M, Ljungberg JK, Nguyen TTK, Zamoshnikova A, Kummari LK, Wyer OJK, Irvine KM, Melo-Bolívar J, Gross A, Brown D, Mak JYW, Fairlie DP, Hansford KA, Cooper MA, Giri R, Schreiber V, Joseph SR, Simpson F, Barnett TC, Johansson J, Dankers W, Harris J, Wells TJ, Kapetanovic R, Sweet MJ, Latomanski EA, Newton HJ, Guérillot RJR, Hachani A, Stinear TP, Ong SY, Chandran Y, Hartland EL, Kobe B, Stow JL, Sauer-Eriksson AE, Begun J, Kling JC, Blumenthal A. Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS Pathog. 2022 Jan 10;18(1):e1010166. doi: 10.1371/journal.ppat.1010166. eCollection 2022 Jan. PMID: 35007292; PMCID: PMC8746789.
Copy Download .nbib Format: NLM
Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve.

Pharmaceuticals (Basel, Switzerland)

Lajoso W, Flower G, Giacco V, Kaul A, La Mache C, Brăban A, Roxas A, Hamilton NB.
PMID: 34577609
Pharmaceuticals (Basel). 2021 Sep 09;14(9). doi: 10.3390/ph14090909.

Oligodendrocytes produce myelin, which provides insulation to axons and speeds up neuronal transmission. In ischaemic conditions, myelin is damaged, resulting in mental and physical disabilities. Recent evidence suggests that oligodendrocyte damage during ischaemia can be mediated by Transient Receptor...

Cite
Lajoso W, Flower G, Giacco V, et al. Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve. Pharmaceuticals (Basel). 2021;14(9)doi: 10.3390/ph14090909.
Lajoso, W., Flower, G., Giacco, V., Kaul, A., La Mache, C., Brăban, A., Roxas, A., & Hamilton, N. B. (2021). Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve. Pharmaceuticals (Basel, Switzerland), 14(9), . https://doi.org/10.3390/ph14090909
Lajoso, Wendy, et al. "Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve." Pharmaceuticals (Basel, Switzerland) vol. 14,9 (2021). doi: https://doi.org/10.3390/ph14090909
Lajoso W, Flower G, Giacco V, Kaul A, La Mache C, Brăban A, Roxas A, Hamilton NB. Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve. Pharmaceuticals (Basel). 2021 Sep 09;14(9). doi: 10.3390/ph14090909. PMID: 34577609; PMCID: PMC8469017.
Copy Download .nbib Format: NLM
Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg.

Frontiers in neurology

Beydoun SR, Sharma KR, Bassam BA, Pulley MT, Shije JZ, Kafal A.
PMID: 33763019
Front Neurol. 2021 Mar 08;12:638816. doi: 10.3389/fneur.2021.638816. eCollection 2021.

Immunoglobulin (Ig) therapy is a first-line treatment for CIDP, which can be administered intravenously (IVIg) or subcutaneously (SCIg) and is often required long term. The differences between these modes of administration and how they can affect dosing strategies and...

Cite
Beydoun SR, Sharma KR, Bassam BA, et al. Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg. Front Neurol. 2021;12:638816doi: 10.3389/fneur.2021.638816.
Beydoun, S. R., Sharma, K. R., Bassam, B. A., Pulley, M. T., Shije, J. Z., & Kafal, A. (2021). Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg. Frontiers in neurology, 12638816. https://doi.org/10.3389/fneur.2021.638816
Beydoun, Said R, et al. "Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg." Frontiers in neurology vol. 12 (2021): 638816. doi: https://doi.org/10.3389/fneur.2021.638816
Beydoun SR, Sharma KR, Bassam BA, Pulley MT, Shije JZ, Kafal A. Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg. Front Neurol. 2021 Mar 08;12:638816. doi: 10.3389/fneur.2021.638816. eCollection 2021. PMID: 33763019; PMCID: PMC7982536.
Copy Download .nbib Format: NLM
Showing 901 to 907 of 907 entries